Menu

Viral Trek to the Brain

Rabies hitches a ride with a receptor for nerve growth factor.

Sep 3, 2014
Molly Sharlach

Dorsal root ganglia explant grown ex vivo; Insert: Rabies virus (green) binds the p75 neurotrophine receptor (red) at the tip of a sensory axon.ERAN PERLSON ET AL.The saliva transmitted by the bite of a rabid animal allows the rabies virus to enter a victim’s muscle tissue. But to cause its trademark symptoms, including violent behavior, rabies must first reach the brain.

The virus begins its journey in the peripheral nervous system by traveling along axons. In a study published last week (August 28) in PLOS Pathogens, a team led by investigators at Tel Aviv University in Israel showed that p75 nerve growth factor receptor, or p75NTR, plays a critical role in viral transport.

Tel Aviv’s Shani Gluska, Eran Perlson, and their colleagues tracked fluorescently labeled viral particles moving along mouse axons grown in specialized microfluidic chambers. Although p75NTR is not required for the virus to travel along an axon, the researchers found that viral particles transported along with p75NTR moved at significantly higher speeds than those not associated with this receptor; this difference, they showed, was due to less frequent, shorter pauses during movement.  In fact, p75NTR transported the virus more quickly than it shuttled nerve growth factor, its endogenous ligand.

The researchers also found that rabies viral particles co-localized and moved together with an acidic marker, suggesting that the viral particles may be transported within membrane compartments. Low pH is known to change the conformation of the viral glycoprotein, which may regulate transport.

The results point to a potential therapeutic target, virologist Monique Lafon of the Pasteur Institute in Paris who was not involved in the work told Science News.

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.